Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 14/20 | 0.47 |
| ▸ | F10 | P00742 | 14/20 | 0.47 |
| ▸ | PLAU | P00749 | 14/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.39 |
| ▸ | NOS2 | P35228 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869903 | 1.00 | F9 (0.47) | F9F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL6277974 | 0.89 | F9 (0.48) | F9F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL5869227 | 0.89 | F9 (0.48) | F9F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL5869599 | 0.89 | F9 (0.48) | F9F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL6272243 | 0.82 | SLC6A2 (0.40) | SLC6A2SLC6A4NOS2CYP2D6KCNH2 | |
| SCHEMBL5869361 | 0.82 | SLC6A2 (0.40) | SLC6A2SLC6A4NOS2CYP2D6KCNH2 | |
| SCHEMBL5869233 | 0.82 | SLC6A2 (0.40) | SLC6A2SLC6A4NOS2CYP2D6KCNH2 | |
| Fumaric Acid SCHEMBL5869595 | 0.79 | NOS2 (0.55) | F9F10PLAUSLC6A2SLC6A4 | |
| Fumaric Acid SCHEMBL5869456 | 0.79 | NOS2 (0.55) | F9F10PLAUSLC6A2SLC6A4 | |
| SCHEMBL5869158 | 0.79 | NOS2 (0.44) | SLC6A2SLC6A4NOS2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037932-B2 | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1397129-B1 | HETEROARYLOXY 3-SUBSTITUTED PROPANAMINES S SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS | LILLY CO ELI (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ELI LILLY AND COMPANY | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176435-A1 | Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors | ADRA2C, ADRB1, TPH1 | F9 2043/4885F10 2617/4885PLAU 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.